Larry Krevolin, DO
Nephrology · Philadelphia, PANPI 1265532923
Payments from drug & device makers
Across 513 payments — averaging $78.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$25K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$7K
- Vifor Pharma, Inc.$1K
- Amgen$1K
- AstraZeneca$925
- OPKO Pharmaceuticals, LLC$859
- plus $4K from 26 others
What the payments were for
- Consulting fees$7,01717%
- Speaking & faculty fees$23,49258%
- Travel & lodging$1160%
- Food & beverage$9,26923%
- Education$3661%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 51 | $25,086 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 11 | $7,279 |
| Vifor Pharma, Inc. | 47 | $1,145 |
| Amgen(2 entities) | 43 | $1,010 |
| AstraZeneca(2 entities) | 52 | $925 |
| OPKO Pharmaceuticals, LLC | 130 | $859 |
| Otsuka America Pharmaceutical, Inc. | 24 | $424 |
| Fresenius USA Marketing, Inc. | 23 | $385 |
| Novo Nordisk | 11 | $377 |
| Travere Therapeutics, Inc. | 13 | $317 |
| Novartis | 18 | $312 |
| Mallinckrodt Hospital Products Inc. | 14 | $310 |
| GSK | 11 | $240 |
| Ardelyx, Inc. | 9 | $208 |
| Arbor Pharmaceuticals, Inc. | 11 | $204 |
| Calliditas Therapeutics US Inc. | 8 | $198 |
| Pharmacosmos Therapeutics Inc. | 2 | $160 |
| Aurinia Pharma U.S., Inc. | 5 | $107 |
| Biomerieux Inc | 2 | $103 |
| Akebia Therapeutics Inc | 4 | $88 |
| Mallinckrodt Enterprises LLC | 3 | $69 |
| Lilly USA, LLC | 3 | $69 |
| Octapharma USA, Inc. | 3 | $65 |
| Azurity Pharmaceuticals, Inc. | 3 | $56 |
| Sanofi | 2 | $47 |
| Boehringer Ingelheim | 2 | $45 |
| Daiichi Sankyo Inc. | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Scpharmaceuticals Inc. | 1 | $30 |
| Amarin Pharma, Inc. | 2 | $28 |
| Apellis Pharmaceuticals, Inc. | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,260 in reported general payments places this provider in the 90th percentile of 586 nephrology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KerendiaFinerenone | 20 | $19,768 |
| FarxigaDapagliflozin Propanediol | 17 | $17,237 |
| Sevelamer Carbonate | 93 | $16,238 |
| Cinacalcet Hcl | 20 | $13,490 |
| EliquisApixaban | 14 | $11,700 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 38 | $10,633 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 16 | $8,293 |
| LokelmaSodium Zirconium Cyclosilicate | 20 | $6,959 |
| EdarbiAzilsartan Medoxomil | 12 | $5,114 |
| Clonidine | 48 | $4,916 |
| Calcium Acetate | 70 | $4,374 |
| VascepaIcosapent Ethyl | 11 | $3,158 |
| Nifedipine ErNifedipine | 32 | $2,023 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 30 | $1,509 |
| Valsartan | 43 | $1,213 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $925 | $24,19637 claims |
| BayerKerendia | $25,086 | $19,76820 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $204 | $13,40728 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 586 nephrology providers in Pennsylvania.
Other nephrology in Philadelphia
- Katalin SusztakPhiladelphia$4.8M
- Debbie Cohen SteinPhiladelphia$2.8M
- Iris LeePhiladelphia$1.9M
- Abdallahsassine GearaPhiladelphia$1.2M
- Gaia MuallemPhiladelphia$942K
- Rakesh GulatiPhiladelphia$660K
- Roy BloomPhiladelphia$575K
- Jonathan HoganPhiladelphia$551K
- Laura DemberPhiladelphia$550K
- Kwabena NtosoPhiladelphia$482K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.